Acute ST-Elevation Myocardial Infarction
Conditions
Brief summary
Cardiovascular magnetic resonance imaging enables comprehensive assessment of cardiovascular function, morphology and pathology. The investigators aim to evaluate the nature and clinical significance of magnetic resonance imaging parameters in patients presenting with first acute ST-elevation myocardial infarction.
Interventions
DIAGNOSTIC_TESTCardiovascular Magnetic Resonance Imaging
Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
Sponsors
Medical University Innsbruck
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* First ST-elevation myocardial infarction according to the European Society of Cardiology/American College of Cardiology committee criteria * Primary percutaneous coronary intervention within 24 hours after symptom onset
Exclusion criteria
* Age \< 18 years * Any history of a previous myocardial infarction or coronary intervention * Clinically unstable patients (Killip class \>2) * Renal failure (estimated glomerular filtration rate \< 30 ml/min/1.73 m2) * Contraindications to cardiac magnetic resonance imaging (pacemaker, cerebral aneurysm clip, orbital foreign body, known or suggested contrast allergy to gadolinium, claustrophobia) * Inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurence of major adverse cardiovascular events | 1 - 5 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of infarct transmurality grade (%) with late gadolinium enhancement imaging | baseline, 4 months and 12 months | — |
| Occurence and area of microvascular obstruction | baseline | — |
| Intramyocardial haemorrhage assessed by T2* imaging | baseline, 4 months and 12 months | — |
| Tissue characterisation by T1, T2 and T2* Mapping | baseline, 4 months and 12 months | — |
| Myocardial deformation by strain analysis | baseline, 4 months and 12 months | — |
| Chamber volumes by cine imaging | baseline, 4 months and 12 months | — |
| Cardiac function by cine imaging | baseline, 4 months and 12 months | — |
| Infarct size assessment (% of left ventricular myocardial mass) | baseline, 4 months and 12 months | — |
| Aortic pulse wave velocity and distensibility by phase contrast imaging | baseline, 4 months and 12 months | — |
| Aortic pulse wave distensibility by phase contrast imaging | baseline, 4 months and 12 months | — |
| Quality of life and invalidity assessment (Global Physical Activity Questionnaire) | 1 - 5 years | — |
| Biomarker release during the acute and subacute phase | baseline, 4 months and 12 months | biomarker concentrations of hemodynamic stress (n-terminal pro-B-type natriuretic peptide), neurohumoral markers (i.e. neprilysin ng/ml), inflammatory markers (i.e. procalcitonin µg/l) and markers of myocardial injury (i.e. high sensitivity cardiac troponin T ng/l) |
| Parameters of cardiac function by transthoracic echocardiography | baseline, 4 months and 12 months | — |
| Plaque volume by 3D ultrasound | baseline, 12 months | — |
| Cardiac autonomic function | baseline, 4 months and 12 months | Deceleration capacity of heart rate |
| Stroke volumes by phase contrast imaging | baseline, 4 months and 12 months | — |
Countries
Austria
Contacts
Primary ContactBernhard Metzler, MD, MSc
Backup ContactGert Klug, MD
Outcome results
None listed